Kursprognose für BioCryst Pharmaceuticals, Inc. (BCRX)BCRXBioCryst Pharmaceuticals, Inc.

Alphio's BCRX stock price prediction model matches the current BioCryst Pharmaceuticals, Inc. tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $7.88 (+1.27%). The 1-week path is $8.06 (+3.66%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

BioCryst Pharmaceuticals Inc (BCRX) is currently trading at $7.79, which is below the average analyst price target of $12 to $13, indicating potential upside. However, the stock has a low RSI of 27.65, suggesting it is oversold, but recent performance shows a 5-day decline of 8.89%, reflecting negative sentiment. The main risk is the downgrade by RBC, which has lowered its price target to $11 due to competitive pressures affecting revenue from Orladeyo, which is projected to drop to $400 million to $450 million in the long term. Therefore, while there is potential for recovery, the current market conditions and analyst sentiment suggest holding rather than buying at this moment.

BioCryst Pharmaceuticals, Inc. (BCRX) last closed at $7.78, gaining +0.39%. These facts feed the 1-day and 1-week BCRX price prediction above.